Publications by authors named "Christian Gordillo"
Article Synopsis
- BCMA-targeting CAR-T cells are now a key treatment for relapsed/refractory multiple myeloma, with patient outcomes linked to T cell expansion post-infusion.
- A study involving 156 patients found that those with higher maximum absolute lymphocyte count (ALCmax) showed significantly improved depth of response and progression-free survival.
- ALCmax over 1.0 × 10^3/μL correlates with better outcomes, while lower counts indicate a higher risk of disease progression, suggesting ALC can serve as an important prognostic marker.
Article Synopsis
- Hematopoietic cell transplant (HCT) patients often have low antibody levels to diseases like tetanus, diphtheria, and pertussis, and there's been no prior research comparing the effectiveness of DTaP and Tdap vaccines in these individuals.
- A study involving 43 HCT recipients found that those who received DTaP had significantly higher antibody levels for all three vaccine components and a greater number of strong responders compared to those who received Tdap.
- The results suggest that DTaP could be a more effective option for vaccinating HCT patients, leading to better immune responses.
Article Synopsis
- Both autologous (auto-HCT) and allogeneic (allo-HCT) hematopoietic cell transplantation significantly alter the intestinal microbiome, but the specific impacts of antibiotic use and alloreactivity are still unclear.
- A study compared the microbiome diversity of auto-HCT and allo-HCT recipients before and up to 100 days after transplantation, analyzing how antibiotics and different transplant types affect microbiome recovery.
- Results showed that allo-HCT recipients initially had lower microbiome diversity due to higher pre-transplant antibiotic use, and while diversity declined post-transplant, it generally returned to baseline by day 100, with antibiotic exposure having a major impact on these changes.
Background: Tocilizumab, an interleukin-6 receptor blocker, has been used in the inflammatory phase of COVID-19, but its impact independent of corticosteroids remains unclear in patients with severe disease.
Methods: In this retrospective analysis of patients with COVID-19 admitted between March 2 and April 14, 2020 to a large academic medical center in New York City, we describe outcomes associated with tocilizumab 400 mg (without methylprednisolone) compared to a propensity-matched control. The primary endpoints were change in a 7-point ordinal scale of oxygenation and ventilator free survival, both at days 14 and 28.
Gastrointestinal side effects are the dose-limiting toxicity of high-dose melphalan (HDM) in autologous hematopoietic stem-cell transplantation, but there are limited contemporary data on the incidence and severity of gastrointestinal toxicity associated with this regimen. We retrospectively studied 100 consecutive patients who received HDM alone or in combination with other conditioning agents. Patients had a median age of 56 (range 20-73); underlying diseases were myeloma (42%), lymphoma (42%), or amyloidosis (16%) and melphalan dosages were 200 (40%), 140 (59%), or 100 mg/m (1%).
View Article and Find Full Text PDFArticle Synopsis
- Cytomegalovirus (CMV) reactivation poses serious health risks for patients after allogeneic hematopoietic cell transplantation (AHCT), and the risk increases with graft versus host disease (GVHD).
- A study analyzed 20 patients who received letermovir beyond 100 days post-transplant and found that only one patient (5%) developed significant CMV infection needing treatment, while no patients developed CMV organ disease.
- Results suggest that extended use of letermovir is effective in preventing clinically significant CMV infections in patients suffering from GVHD.
Unlabelled: Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academic centers in New York City in the spring of 2020, during which it was a global epicenter of the SARS-CoV-2 pandemic. Of 100 patients with multiple myeloma (male 58%; median age 68) diagnosed with COVID-19, 75 were admitted; of these, 13 patients (17%) were placed on invasive mechanical ventilation, and 22 patients (29%) expired.
View Article and Find Full Text PDFImportance: New York City is a global epicenter for the SARS-CoV-2 outbreak with a significant number of individuals infected by the virus. Patients with multiple myeloma have a compromised immune system, due to both the disease and anti-myeloma therapies, and may therefore be particularly susceptible to coronavirus disease 2019 (COVID-19); however, there is limited information to guide clinical management.
Objective: To assess risk factors and outcomes of COVID-19 in patients with multiple myeloma.